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ABSTRACT
Objectives: Previous studies have shown that a
majority of patients cite altruistic motives, such as
contributing to generalisable medical knowledge, as
factors motivating clinical trial participation. We sought
to examine the impact of making trial results publicly
available on patients’ willingness to participate in
clinical research.
Design: Cross-sectional analysis using a questionnaire
developed by a panel with expertise in publication bias,
informed consent and survey design.
Setting: A single urban, academic emergency
department (ED) in the Northeastern USA.
Participants: 799 ED patients.
Outcome Measures: We assessed (1) participants’
attitudes towards clinical trial participation, and (2) the
impact of whether study results would eventually be
made publicly available or not on willingness to
participate in a trial.
Results: Of 799 patients surveyed, 36% (95% CI 32%
to 39%) reported that they would generally like to
participate in a trial, and another 50% (95% CI 47% to
54%) reported that they would consider participation
depending on study details. For the majority of
participants, the publication of trial results was either
important (36%; 95% CI 33% to 40%) or very
important (48%; 95% CI 44% to 51%). Most (63%;
95% CI 59% to 66%) reported they would be less
likely to participate in a trial if investigators had not
publicly released results from a prior study.
Additionally, 85% (95% CI 82% to 87%) felt that it
was important or very important to receive information
about the publication track record of sponsors and
investigators during the informed consent process.
Conclusions: The majority of patients in this sample
would consider participation in a clinical trial. Patients
value the public release of trial results, and believe that
the informed consent process should address the
possibility of non-publication.
INTRODUCTION
Clinical trials are critical to the advancement
of medical knowledge. The vast majority of
trials involve an informed consent process, in
which investigators inform potential partici-
pants about the anticipated risks and pos-
sible benefits of taking part in a trial and
ensure that those patients who participate do
so willingly.1 The informed consent process
has evolved over the past several decades to
better ensure patient autonomy. Continuing
to identify what information potential partici-
pants feel is important to disclose during the
informed consent process is of the utmost
importance to ensure that patients can make
a truly informed decision about participation
in clinical trials.
Previous studies have found that a large
proportion of patients cite altruistic motives,
such as potential benefit to others and con-
tributing to generalisable medical knowl-
edge, as motivating factors to participate in a
clinical trial.2–6 However, many clinical trials
are never published: an estimated 50% of all
clinical trials are not published and almost a
third of trials involving more than 500 parti-
cipants are not published.7–12 Several clinical
trial registries, including ClinicalTrials.gov,
now have results databases which allow inves-
tigators to share trial results independent of
publication. However, only a minority of
Strengths and limitations of this study
▪ This study is unique in that it offers insight into
the problem of non-publication from the per-
spective of research participants.
▪ The study used a pilot phase, recruited patients
via random time block sampling, and assessed
test–retest reliability in order to limit study bias.
▪ This is a single-centre study involving an urban
emergency department in the USA; results may
not be applicable to other patient populations.
▪ The results from this cross-sectional study are
subject to selection bias.
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unpublished trials utilise these resources, and peer-
reviewed publication remains the primary way by which
trial results are made available to the scientific commu-
nity.8 13 Non-publication therefore greatly limits the
potential of a trial to benefit others or increase medical
knowledge.
It is unknown whether potential research participants
are aware that failure to publicly release trial data is a
problem, whether the release of trial results is important
to potential study participants, and whether awareness of
the possibility of non-publication might influence deci-
sions about trial participation. The primary objective of
this investigation was to examine how the possibility of
non-publication might influence attitudes towards trial
participation.
MATERIALS AND METHODS
This study was performed from January to April 2015 at
Cooper University Hospital, an urban, academic emer-
gency department (ED) serving a socioeconomically
diverse community in the Northeastern USA. Eligible
participants were English speaking and at least 18 years.
Patients were excluded if they had an abnormal mental
status, an acute psychiatric emergency or were critically
ill, as defined by an emergency severity index (ESI)
score of 1. Patients evaluated in our department’s ‘fast
track’ were also excluded, as these patients are often dis-
charged rapidly, before consent for participation and
completion of data collection can be performed.
We modified a previously published survey assessing
reasons for trial participation.3 Construct validity of the
modified survey was ensured through an iterative
process of expert panel review, feedback and revision.
This panel included members with expertise in publica-
tion bias, the informed consent process, research ethics
and survey design. The completed instrument was
piloted on 20 participants; no substantive changes were
made following this pilot phase. The new survey con-
sisted of questions assessing factors motivating participa-
tion in clinical research and opinions regarding the
informed consent process.
Research assistants received their initial training on
the study protocol during a didactic lecture session. An
investigator then observed each research assistant and
provided feedback on their interactions with enrolled
participants until the research assistants each demon-
strated proficiency with screening participants, obtaining
informed consent and performing data collection.
Research assistants screened and enrolled participants
using random time block sampling, in which screening
occurred during randomly selected 2-hour blocks
between 9:00 and 22:00, 7 days per week. We used
random time block sampling in order to minimise sam-
pling bias due to convenience sampling and to obtain a
broad sample of participants, given limited resources
available for data collection. Test–retest reliability was
assessed among the first 50 participants who were
admitted to the hospital and were therefore available for
reassessment between 24 and 72 hours after their initial
enrolment. These participants were administered a
second survey which mirrored the first, but with changes
in the exact syntax and order of the included questions.
Initial and subsequent responses were then compared to
assess the stability of responses to survey questions.
All data were entered into Research Electronic Data
Capture (REDCap), a secure, web-based application
designed to support data capture for research studies,
and exported into SPSS V.20.0 (IBM Corp, Armonk,
New York, USA) for analysis.14 We calculated descriptive
statistics for the collected survey data. The χ2 test was
used to compare responses among four predefined
sociodemographic groups: sex, age (≥65 vs 18–64), race
(whites vs Caucasians) and formal education (college
degree vs no college degree). Missing data were
excluded on a pairwise basis. p Values of <0.05 were con-
sidered statistically significant. The Cooper University
Hospital Institutional Review Board (IRB) approved the
study protocol with verbal consent.
RESULTS
A total of 3509 patients were screened, of which 1691
were eligible for participation, and 799 (47%) agreed to
participate (figure 1). The study sample was diverse in
regard to race and formal education; 16% had previ-
ously participated in a clinical research study (table 1).
Forty-six per cent of study participants were discharged
home following their ED evaluation, 18% were placed in
observation status and 35% were admitted to the
hospital.
Study participants largely recognised the key role that
clinical trials play in making medical progress, with 95%
(95% CI 93% to 96%) describing clinical trials as being
either important or very important in the advancement
of medical treatments. Among those surveyed, 286
(36%; 95% CI 32% to 39%) reported that they would
generally like to participate in a trial, and 401 (50%;
95% CI 47% to 54%) reported that they would consider
Figure 1 Flow chart of eligible patients.
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participation depending on the details of the study
(table 2).
Patients reported they would be strongly motivated to
participate in clinical trials in order to establish or main-
tain a good relationship with their treating physician
and in order to facilitate close monitoring of their own
health (table 3). Additionally, 85% (95% CI 83% to
88%) of patients considered the possibility of benefit to
future patients to be an important or very important
factor motivating trial participation. Access to experi-
mental interventions and reimbursement for participa-
tion were regarded as less influential factors in
determining trial participation.
For most participants, the public release of trial results
was either important (36%) or very important (48%)
(table 4). Participants underestimated typical delays
between trial completion and release of results (median
estimate 12 months (IQR 6–18)), and estimated rates of
failure to release results varied widely (mean 51%, SD
27%). Sixty-three per cent (95% CI 59% to 66%) would
be less likely to participate in a trial if investigators had
not publicly released prior study results. Additionally,
85% (95% CI 82% to 87%) felt that receiving informa-
tion about the publication track record of sponsors and
investigators during the informed consent process was
important or very important.
Views on trial participation remained largely stable
among the participants evaluated in the ED and again
during their hospital admission. Within this group
of 50 participants, 46% (95% CI 32% to 60%) had
a positive attitude towards trial participation when
approached in the ED and 40% (95% CI 26% to 54%)
had a positive attitude towards trial participation when
reapproached during their hospitalisation. Attitudes
towards specific factors motivating participation also
remained generally stable (see online supplementary
appendix).
There were no significant differences in attitudes
towards clinical trials or willingness to participate in a
trial by patient gender or age ≥65 years. Whites were
more likely than non-whites to have a very positive or
positive attitude towards trials in general (64% vs 53%,
p<0.001) and more likely to have a positive or neutral
attitude towards personal participation in a trial than
non-whites (89% vs 83%; p=0.03). Participants with a
college degree were also more likely to view trials very
positively or positively than participants who had not
graduated from college (64% vs 56%, p<0.01).
DISCUSSION
Numerous prior investigations have shown that approxi-
mately one-third to one-half of completed clinical trials
never have results published in a peer-reviewed
journal.7–9 15 16 Failure to publicly release clinical trial
results is a major threat to the validity of the medical lit-
erature, and addressing this problem is an active area of
policy effort nationally and internationally.17–19
Although study participants often cite contributing to
knowledge as a reason for participation in clinical trials,
consent forms rarely if ever describe the potential that
results might not be made publicly available. In this
large study of attitudes among a diverse group of poten-
tial clinical trial participants, we observe that the major-
ity of participants placed substantial value on the release
of trial results. Specifically, we find that a majority of the
participants in our study would be less likely to partici-
pate in a new trial if the investigators had not released
Table 1 Characteristics of study participants
Characteristic
Participants
(n=799)
Age, mean (SD) 50 (17)
Female sex, n (%) 468 (59)
Race, n (%)*
White 405 (51)
Black 259 (32)
Asian 14 (2)
Other 124 (14)
Highest level of education, n (%)
Some high school or high school graduate 389 (49)
Some college 176 (22)
College graduate 160 (20)
Advanced degree 51 (6)
Unknown 23 (3)
Previous participation in a clinical research
study, n (%)
131 (16)
*Respondents could select more than one answer.
Table 2 General attitudes towards clinical trials
Question Answer choices N (%)
What is your general
attitude towards clinical
trials?
Very positive 167 (21)
Positive 300 (38)
Positive with
reservations
178 (22)
Generally negative,
but realise necessity
43 (5)
Negative 25 (3)
No opinion 86 (11)
What is your general
attitude towards
personally participating
in a clinical trial?
Positive—would
generally like to
participate
286 (36)
Neutral—would
depend on the study
details
401 (50)
Negative—would
generally not want to
participate
112 (14)
How important do you
think clinical trials are to
making advances in
medical treatments?
Very important 539 (68)
Important 217 (27)
Minor importance 23 (3)
Not important 19 (2)
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results from a previous clinical trial, and a majority felt
that the publication track records of investigators and
sponsors should be disclosed during the informed
consent process.
Clinical trial registries were developed in part to make
it easier for the scientific community to identify, track
and obtain results from unpublished trials.20
Additionally, registries have the potential to improve
awareness among prospective and actual trial participants
with respect to the prior publication track records of
investigators and sponsors, and they also provide trial par-
ticipants with the a mechanism to track the publication
status of the trial in which they took part. To this end, in
order to comply with the Food and Drug Amendments
Act of 2006 (FDAAA), applicable clinical trials initiated
on or after 7 March 2012 have been required to include
the following language in informed consent documents:
‘A description of this clinical trial will be available on
Table 4 Patient attitudes towards the making trial results publically available
Question Answer choices N (%)
If you knew that a study sponsor or investigator had not made results
from previous trials publicly available, would this affect your decision to
participate in a new trial run by the same group?
More likely to participate 96 (12)
Less likely to participate 499 (63)
No impact 204 (26)
How important is it to you that the people who did the study make the
results from a trial that you took part in publicly available?
Very important 383 (48)
Important 291 (36)
Minor importance 78 (10)
Not important 47 (6)
How important is it to you that the people who did the study make the
results from a trial that you took part in available to you personally?
Very important 413 (52)
Important 264 (33)
Minor importance 69 (9)
Not important 52 (7)
As part of the informed consent process, how important would it be to
you as a potential trial participant to know whether the people
sponsoring or running the trial had made the results from previous trials
available to the public?
Very important 385 (48)
Important 290 (36)
Minor importance 66 (8)
Not important 58 (7)
Table 3 Factors influencing trial participation
Question: If you were asked about participation in a clinical trial and you
accepted, what would the reason(s) for your acceptance be? Answer choices N (%)
The wish to get the ‘new’ drug Very important 274 (34)
Important 309 (39)
Minor importance 133 (17)
Not important 83 (10)
The wish to help future patients by testing new drugs Very important 362 (45)
Important 321 (40)
Minor importance 57 (7)
Not important 59 (7)
The wish to have your health monitored closely by study physicians and nurses Very important 475 (60)
Important 233 (29)
Minor importance 54 (7)
Not important 35 (4)
The wish to have a good relationship with your treating physician Very important 509 (64)
Important 217 (27)
Minor importance 36 (5)
Not important 37 (5)
Positive experiences from participation in other research studies Very important 310 (39)
Important 318 (40)
Minor importance 61 (8)
Not important or not
applicable
109 (14)
Payment for your time spent participating in the trial Very important 217 (27)
Important 227 (28)
Minor importance 181 (23)
Not important 174 (22)
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http://www.ClinicalTrials.gov, as required by U.S. Law.
This Web site will not include information that can iden-
tify you. At most, the Web site will include a summary of
the results. You can search this Web site at any time’.21
However, the impact of this policy is likely limited. First,
many trials do not meet the FDAAA definition of an
‘applicable clinical trial’, and therefore, investigators are
not required to inform potential participants about the
trial’s registration status in the first place.22 23 Second, as
with other aspects of the FDAAA, the capacity for
enforcement of this aspect of the law is limited and the
degree to which study sponsors comply is unknown.
Finally, although use of this language in the consent
may raise awareness of trial registration among partici-
pants in applicable clinical trials, identifying a specific
trial within ClinicalTrials.gov often requires a relatively
high degree of scientific literacy, and many trial partici-
pants may not be able to identify the registry entry for
their specific trial based on the information available
to them.
IRBs are responsible for protecting the interests of
human research participants.24 Our results identify the
public release of trial results as an explicitly stated inter-
est of study participants, and raise the question of how
best to ensure that this interest is protected. Several pos-
sible changes in the current approach to informed
consent could address this challenge. First, in the case
of applicable trials under the FDAAA, the unique trial
identifier number assigned to each individual trial could
be included in the consent form in order to facilitate
identification of the trial’s specific registry entry.
Second, local IRBs should consider requiring all trials,
even those that do not meet FDAAA criteria as applic-
able clinical trials, to report their registration status
and registry identification number to prospective partici-
pants. Third, although most investigators cannot
anticipate non-publication, some information might be
presented in the consent process regarding the publica-
tion of results. For FDAAA eligible studies, availability
of study results within 1 year of study completion is
required by law unless the responsible party obtains an
extension, but compliance with this requirement is
poor.23 For all studies, the investigator’s and the spon-
sor’s track record of making results public could be
included in the consent. Importantly, these proposed
changes to the informed consent process have the
potential to cause unintended consequences, and the
effects on decision-making among prospective trial parti-
cipants as well as patient accrual should be studied.
Additionally, it may be challenging to find the ideal
balance between providing enough information to
inform enrolment decisions while avoiding the introduc-
tion of unnecessary complexity into the informed
consent process. Collectively, however, these changes
might help study participants make more informed deci-
sions regarding participation and increase pressure on
investigators and sponsors to make results of clinical
trials publicly available.
Limitations
Several limitations should be considered when interpret-
ing these results. First, this study was performed in the
ED of a single urban, academic medical centre located
in the Northeastern USA. The population sampled in
this study may be quite different from the target popula-
tion for some clinical trials. In particular, these results
may not apply to phase I trials, which involve healthy
volunteers rather than patients. However, EDs provide
access to a racially and socioeconomically diverse popu-
lation and are often used to recruit patients for interven-
tional studies involving patients with acute injuries or
illnesses. Second, 53% of otherwise eligible patients
refused to participate. For some, refusal likely reflects
the symptom burden and time constraints faced by
patients receiving care in the ED. For others, refusal
likely reflects a lack of interest in contributing to the
study. While this somewhat limits the generalisability of
these data, the patients who declined to participate in
the present study are also probably less likely to partici-
pate in a clinical trial and so their answers would be less
relevant than answers from those patients who were
willing to participate. Third, it is possible that the act of
asking participants to answer questions regarding the
release of trial data may have influenced their stated
views on the topic. Participants may not have recognised
the failure to release trial results as a potential problem
prior to being asked about it, or their opinions about
the importance of non-publication may have changed as
a result of participating in the study. Finally, we asked
patients questions about participation in a hypothetical
study; answers given under these circumstances might
not accurately reflect behaviour when faced with the
choice of actually participating in a specific trial for an
active medical problem.
CONCLUSIONS
The desire to contribute to generalisable medical knowl-
edge is a strong motivating factor for research partici-
pants. Participants place substantial value on the public
release of trial results, and believe that the informed
consent process should address the possibility of
non-publication.
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